Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Solid Biosciences Inc (SLDB)

Solid Biosciences Inc (SLDB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 461,227
  • Shares Outstanding, K 77,910
  • Annual Sales, $ 0 K
  • Annual Income, $ -124,700 K
  • EBIT $ -170 M
  • EBITDA $ -171 M
  • 60-Month Beta 2.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.82

Options Overview Details

View History
  • Implied Volatility 651.48% (-37.16%)
  • Historical Volatility 95.03%
  • IV Percentile 96%
  • IV Rank 52.92%
  • IV High 1,154.33% on 11/07/25
  • IV Low 86.30% on 06/16/25
  • Expected Move (DTE 14) 0.85 (14.36%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 133
  • Volume Avg (30-Day) 174
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 7,766
  • Open Int (30-Day) 7,726
  • Expected Range 5.07 to 6.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.48
  • Number of Estimates 7
  • High Estimate -0.38
  • Low Estimate -0.51
  • Prior Year -0.89
  • Growth Rate Est. (year over year) +46.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.79 +54.93%
on 11/07/25
5.97 -1.64%
on 12/04/25
+1.94 (+49.41%)
since 11/05/25
3-Month
3.79 +54.93%
on 11/07/25
6.79 -13.52%
on 10/08/25
+0.37 (+6.76%)
since 09/05/25
52-Week
2.41 +143.65%
on 05/15/25
7.37 -20.33%
on 07/30/25
+0.91 (+18.39%)
since 12/05/24

Most Recent Stories

More News
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac...

SLDB : 5.87 (-0.81%)
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – –...

SLDB : 5.87 (-0.81%)
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

- Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization...

SLDB : 5.87 (-0.81%)
Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

SLDB : 5.87 (-0.81%)
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines -  - New Innovative Licensing and Access Pathway (ILAP) designation...

SLDB : 5.87 (-0.81%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac...

SLDB : 5.87 (-0.81%)
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

-  Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet...

SLDB : 5.87 (-0.81%)
Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

SLDB : 5.87 (-0.81%)
William Blair Sticks to Their Buy Rating for Solid Biosciences (SLDB)

In a report released today, Sami Corwin from William Blair maintained a Buy rating on Solid Biosciences. The company’s shares opened today at $6.06.Elevate Your Investing Strategy: Take advantage of...

SLDB : 5.87 (-0.81%)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac...

SLDB : 5.87 (-0.81%)

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

3rd Resistance Point 6.76
2nd Resistance Point 6.36
1st Resistance Point 6.14
Last Price 5.87
1st Support Level 5.53
2nd Support Level 5.13
3rd Support Level 4.91

See More

52-Week High 7.37
Last Price 5.87
Fibonacci 61.8% 5.48
Fibonacci 50% 4.89
Fibonacci 38.2% 4.30
52-Week Low 2.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar